PLYMOUTH
MEETING, Pa., Jan. 29,
2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancer and infectious diseases, today announced that Dr.
Jacqueline Shea, INOVIO's President
and CEO, and Dr. Michael Sumner,
Chief Medical Officer, will be presenting at the Oppenheimer 35th
Annual Healthcare Life Sciences Conference.
Oppenheimer 35th Annual Healthcare Life Sciences
Conference
Date: Wednesday, February 12,
2025
Time: 3:20 – 3:50 pm ET
Format: Presentation
During the conference, Dr. Shea and members of INOVIO's
management team will conduct one-on-one meetings with registered
investors.
A webcast of the presentation will be available on the INOVIO
Investor Relations Events page at
https://ir.inovio.com/events-and-presentations/default.aspx. A
replay of the webcast will be available for 90 days after the date
of the presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-related diseases, cancer, and infectious diseases. INOVIO's
technology optimizes the design and delivery of innovative DNA
medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
Contacts
Media: Jennie Willson, (267)
429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR
Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302363750.html
SOURCE INOVIO Pharmaceuticals, Inc.
